Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial comparing intravenous JNJ-64179375 to oral apixaban for VTE prophylaxis after total knee replacement has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vte Prophylaxis After Total Knee Replacement

Drugs mentioned

• Apixaban (apixaban)
• JNJ-64179375

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery | Phase 2 | Status: COMPLETED | Results posted: 2019-11-25